NASDAQ:REGNRegeneron Pharmaceuticals Stock Price, Forecast & News

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, REGN stock has increased by 32.5% and is now trading at $615.55.
View which stocks have been most impacted by COVID-19.

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 11 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported $7.16 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $5.59 by $1.57. The biopharmaceutical company earned $1.95 billion during the quarter, compared to analysts' expectations of $1.74 billion. Regeneron Pharmaceuticals had a return on equity of 26.71% and a net margin of 37.30%. The company's revenue for the quarter was up 23.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $6.02 EPS.
View Regeneron Pharmaceuticals' earnings history.

Regeneron Pharmaceuticals declared that its Board of Directors has approved a share repurchase program on Tuesday, November 5th 2019, which authorizes the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 2.9% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company's board of directors believes its shares are undervalued.

27 brokers have issued 12 month price objectives for Regeneron Pharmaceuticals' stock. Their forecasts range from $325.00 to $800.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $592.78 in the next year. This suggests that the stock has a possible downside of 3.7%.
View analysts' price targets for Regeneron Pharmaceuticals.

News stories about REGN stock have trended somewhat negative on Friday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Regeneron Pharmaceuticals earned a news impact score of -1.6 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days.
View the latest news about Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals saw a drop in short interest in the month of June. As of June 30th, there was short interest totaling 2,120,000 shares, a drop of 14.2% from the June 15th total of 2,470,000 shares. Based on an average daily volume of 1,370,000 shares, the short-interest ratio is currently 1.5 days. Approximately 2.0% of the company's stock are sold short.
View Regeneron Pharmaceuticals' Short Interest.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Novavax (NVAX) and Repligen (RGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Johnson & Johnson (JNJ), Micron Technology (MU), Walt Disney (DIS), Visa (V) and Intel (INTC).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (11.33%), Vanguard Group Inc. (7.13%), California Public Employees Retirement System (0.76%), Bank of New York Mellon Corp (0.70%), FIL Ltd (0.51%) and Sumitomo Mitsui Trust Holdings Inc. (0.44%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi.
View institutional ownership trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Candriam Luxembourg S.C.A., LSV Asset Management, Toronto Dominion Bank, Bank of Nova Scotia, Advisor Group Holdings Inc., NN Investment Partners Holdings N.V., and NN Investment Partners Holdings N.V.. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, and Sanofi.
View insider buying and selling activity for Regeneron Pharmaceuticals.

REGN stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., California Public Employees Retirement System, APG Asset Management N.V., Swiss National Bank, Bank of New York Mellon Corp, Robeco Institutional Asset Management B.V., and First Trust Advisors LP.
View insider buying and selling activity for Regeneron Pharmaceuticals.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of REGN stock can currently be purchased for approximately $615.55.

Regeneron Pharmaceuticals has a market capitalization of $67.72 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe.

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]